Mass Spectrometry-Based Biomarker Discovery

Zhou, Weidong; Petricoin, Emanuel F.; Longo, Caterina

doi:10.1007/978-1-4939-6990-6_19

Cited by 27 publications

(19 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MS has shown much progress within two main categories: searching for novel diagnostic biomarkers via comprehensive proteome/metabolome analyses [ 2 , 3 , 4 ] and clinical microbiology testing [ 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 ]. The present review focuses on clinical microbiology testing.…”

Section: Introductionmentioning

confidence: 99%

Current Status of Matrix-Assisted Laser Desorption/Ionization–Time-of-Flight Mass Spectrometry (MALDI-TOF MS) in Clinical Diagnostic Microbiology

2020

View full text Add to dashboard Cite

Mass spectrometry (MS), a core technology for proteomics and metabolomics, is currently being developed for clinical applications. The identification of microorganisms in clinical samples using matrix-assisted laser desorption/ionization–time-of-flight mass spectrometry (MALDI-TOF MS) is a representative MS-based proteomics application that is relevant to daily clinical practice. This technology has the advantages of convenience, speed, and accuracy when compared with conventional biochemical methods. MALDI-TOF MS can shorten the time used for microbial identification by about 1 day in routine workflows. Sample preparation from microbial colonies has been improved, increasing the accuracy and speed of identification. MALDI-TOF MS is also used for testing blood, cerebrospinal fluid, and urine, because it can directly identify the microorganisms in these liquid samples without prior culture or subculture. Thus, MALDI-TOF MS has the potential to improve patient prognosis and decrease the length of hospitalization and is therefore currently considered an essential tool in clinical microbiology. Furthermore, MALDI-TOF MS is currently being combined with other technologies, such as flow cytometry, to expand the scope of clinical applications.

show abstract

Section: Introductionmentioning

confidence: 99%

Current Status of Matrix-Assisted Laser Desorption/Ionization–Time-of-Flight Mass Spectrometry (MALDI-TOF MS) in Clinical Diagnostic Microbiology

2020

View full text Add to dashboard Cite

show abstract

“…For this purpose, mass spectrometry (MS)–based proteomics approaches provide a modern technology for quantitative and qualitative assessment of proteins, enabling peptide sequencing and protein identification with high accuracy and sensitivity [ 19 ]. This technology has been shown to be a valuable tool for the characterization of protein biomarkers by the analysis of protein extracts obtained from experimental or clinical samples on a systemic level [ 20 , 21 ]. Thus, this method could aid in discovering novel biomarkers for forensic time since death estimation purposes by simultaneously analyzing a high number of proteins, which is hardly achieved by conventional hypothesis-driven studies or even trial and error approaches that often require a lot of time, money, and resources.…”

Section: Introductionmentioning

confidence: 99%

Postmortem proteomics to discover biomarkers for forensic PMI estimation

et al. 2019

View full text Add to dashboard Cite

The assessment of postmortem degradation of skeletal muscle proteins has emerged as a novel approach to estimate the time since death in the early to mid-postmortem phase (approximately 24 h postmortem (hpm) to 120 hpm). Current protein-based methods are limited to a small number of skeletal muscle proteins, shown to undergo proteolysis after death. In this study, we investigated the usability of a target-based and unbiased system-wide protein analysis to gain further insights into systemic postmortem protein alterations and to identify additional markers for postmortem interval (PMI) delimitation. We performed proteomic profiling to globally analyze postmortem alterations of the rat and mouse skeletal muscle proteome at defined time points (0, 24, 48, 72, and 96 hpm), harnessing a mass spectrometry-based quantitative proteomics approach. Hierarchical clustering analysis for a total of 579 (rat) and 896 (mouse) quantified proteins revealed differentially expressed proteins during the investigated postmortem period. We further focused on two selected proteins (eEF1A2 and GAPDH), which were shown to consistently degrade postmortem in both rat and mouse, suggesting conserved intra- and interspecies degradation behavior, and thus preserved association with the PMI and possible transferability to humans. In turn, we validated the usefulness of these new markers by classical Western blot experiments in a rat model and in human autopsy cases. Our results demonstrate the feasibility of mass spectrometry–based analysis to discover novel protein markers for PMI estimation and show that the proteins eEF1A2 and GAPDH appear to be valuable markers for PMI estimation in humans. Electronic supplementary material The online version of this article (10.1007/s00414-019-02011-6) contains supplementary material, which is available to authorized users.

show abstract

“…MS has been implemented as a diagnostic tool, being especially used in drug monitoring [29], newborn screening [30] and in the diagnosis of metabolic diseases [31]. In clinical research, the focus of mass spectrometric analysis has been on biomarker discovery, including proteomics, lipidomics and metabolomics [32,33].…”

Section: Ms-based Methods For Intraoperative Tumor Diagnosticsmentioning

confidence: 99%

Mass Spectrometry-Based Intraoperative Tumor Diagnostics

et al. 2019

View full text Add to dashboard Cite

In surgical oncology, decisions regarding the amount of tissue to be removed can have important consequences: the decision between preserving sufficient healthy tissue and eliminating all tumor cells is one to be made intraoperatively. This review discusses the latest technical innovations for a more accurate tumor margin localization based on mass spectrometry. Highlighting the latest mass spectrometric inventions, real-time diagnosis seems to be within reach; focusing on the intelligent knife, desorption electrospray ionization, picosecond infrared laser and MasSpec pen, the current technical status is evaluated critically concerning its scientific and medical practice.

show abstract

Mass Spectrometry-Based Biomarker Discovery

Cited by 27 publications

References 19 publications

Current Status of Matrix-Assisted Laser Desorption/Ionization–Time-of-Flight Mass Spectrometry (MALDI-TOF MS) in Clinical Diagnostic Microbiology

Current Status of Matrix-Assisted Laser Desorption/Ionization–Time-of-Flight Mass Spectrometry (MALDI-TOF MS) in Clinical Diagnostic Microbiology

Postmortem proteomics to discover biomarkers for forensic PMI estimation

Mass Spectrometry-Based Intraoperative Tumor Diagnostics

Contact Info

Product

Resources

About